2 Information about venetoclax
Marketing authorisation indication
2.1 Venetoclax (Venclyxto, AbbVie) is indicated for 'the treatment of CLL:
-
in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B‑cell receptor pathway inhibitor, or
-
in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B‑cell receptor pathway inhibitor'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics for venetoclax.
Price
2.3 The list price of venetoclax is £4,789.47 per 112‑tablet pack (100 mg; excluding VAT; BNF online accessed February 2022). The average cost for year 1 is £58,752.23 and for year 2 onwards is £41,126.56.
2.4 The company has a commercial arrangement. This makes venetoclax available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.